Company intelligence / Profile preview

Mitochon Technologies

Ownership: Private
Development stage: Preclinical

Overview

Multiple phase 2 studies are being initiated with BGP-15, the company's lead compound that targets cellular stress responses including heat shock protein and mitochondrial stress responses.

Therapeutic areas: Metabolic DisordersRare DiseasesNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

BGP-15

Pre-clinical

Indications: Neurodegenerative diseases, Metabolic diseases

Partnerships

N-Gene Inc.

Beyond the preview

Go deeper on Mitochon Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochon Technologies.